Astellas Licenses Dyno Capsid for Muscle Gene Therapy
April 8, 2026
Astellas and Dyno Therapeutics agreed a $15M+ deal for an AI-designed AAV capsid optimised for muscle-disorder gene therapy delivery, extending Dyno's partnering track record.
April 8, 2026
Astellas and Dyno Therapeutics agreed a $15M+ deal for an AI-designed AAV capsid optimised for muscle-disorder gene therapy delivery, extending Dyno's partnering track record.